"Epiphany Dermatology of Overland Park is located just off I-435, on the 4th floor of the Sarah Cannon Cancer Center building. This premier dermatology center serves greater Kansas City and our experts specialize in the diagnosis and treatment of complex skin diseases. Our extensive collection of lasers, fillers, and non-surgical techniques also allow us to treat most cosmetic concerns."

During the past decade, Kansas City Dermatology, PA conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 19 clinical trials were completed, i.e. on average, 67.9% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 17 clinical trials were completed. i.e. 141.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kansas City Dermatology, PA" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Amgen" with 4 trials sponsored, "Pfizer" with 4 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored and "Cassiopea SpA" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kansas City Dermatology, PA" #1 collaborator was "Dermira, Inc." with 3 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Basilea Pharmaceutica" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Kansas City Dermatology, PA" are "Atopic Dermatitis" (11 trials), "Plaque Psoriasis" (6 trials), "Acne Vulgaris" (4 trials), "Psoriasis" (4 trials) and "Dermatitis, Atopic" (3 trials). Many other conditions were trialed in "Kansas City Dermatology, PA" in a lesser frequency.

Most popular intervention types in "Kansas City Dermatology, PA" are "Drug" (27 trials), "Biological" (5 trials), "Other" (5 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Lebrikizumab" (4 trials), "Abrocitinib 200 mg" (2 trials), "CB-03-01 cream, 1%" (2 trials) and "Guselkumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kansas City Dermatology, PA" are 32 trials for "All" genders.

Currently, there are NaN active trials in "Kansas City Dermatology, PA". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Kansas City Dermatology, PA, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Kansas City Dermatology, PA, 0 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".